TriVascular Technologies (TRIV) Misses Q2 EPS by 21c

TriVascular Technologies (NASDAQ: TRIV) reported Q2 EPS of ($0.87), $0.21 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.54 million.

"We had a strong second quarter reflecting ongoing momentum in commercializing our innovative Ovation Stent Graft platform. We also continued to execute well on our clinical and product development initiatives with the goal of safely expanding EVAR therapy to more patients while also improving EVAR experience for patients and physicians," said President and Chief Executive Officer, Chris Chavez. "Our focus remains clear - to help physicians improve the lives of patients suffering from aortic disease through excellence in research, manufacturing and service."

For earnings history and earnings-related data on TriVascular Technologies (TRIV) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24